Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

Inclusion Criteria:

1. Patients able and willing to provide a written informed consent aged 18-75 years.

2. Histologically confirmed resected ductal pancreatic adenocarcinoma (includingadenosquamous carcinoma).

3. Undergone radical resection and confirmed macroscopic complete resection (R0 andR1).

4. Full recovery after surgery; able to start adjuvant treatment within 12 weeks aftersurgery.

5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

6. The main organs function well.

Exclusion Criteria:

1. Patients with other types of non-ductal tumor of the pancreas, including endocrinetumors or acinar cell adenocarcinoma, pancreatoblastoma, and solid-pseudopapillarytumor.

2. Macroscopic incomplete tumor removal (R2 resection).

3. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreaticadenocarcinoma.

4. Presence or history of metastatic or locally recurrent pancreatic adenocarcinoma.

5. CA 19-9> 180 U / ml within 21 days before randomization.

6. The toxicity of previous therapy has not recovered to Grade 1 or below.

7. Known peripheral neuropathy (CTCAE ≥ Grade 2).

8. Known deficiency of dihydropyrimidine dehydrogenase (DPD)

9. Subjects with a confirmed diagnosis of Gilbert's syndrome